Kimberly Rath, PharmD

The chronic spontaneous urticaria treatment landscape has shifted in recent years, with expanding treatment options for patients with refractory disease.

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

A primary care–based collaborative care model significantly cut opioid use, though mental health outcomes remained unchanged.

Novel 3D analysis reveals core tumor niches drive resistance through AP-1 signaling and stromal reprogramming.

A qualitative study found strong support for primary care provider–nephrologist comanagement of chronic kidney disease (CKD), but persistent deficits in CKD understanding remain.

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.

Men fared better under surveillance, while women benefited more from targeted therapies for the treatment of chronic lymphocytic leukemia (CLL) in a new study.

A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring in hematologic malignancies.

Real-world longitudinal data suggest that in CLL, regular immunoglobulin replacement therapy may not reduce, and may even correlate with increased, serious infection rates during treatment periods.

From alveolar injury to extracellular matrix accumulation, the complex biology of pulmonary fibrosis is being unraveled alongside explorations of both Western and traditional Chinese therapies.

Quantitative muscle ultrasound correlates strongly with ambulatory and timed function tests in Duchenne muscular dystrophy, suggesting it could complement or even replace more burdensome assessments.

A comprehensive US analysis showed that progress in multiple myeloma survival has not been shared equally, with significant disparities persisting despite improved therapies.

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared with those receiving zanubrutinib, according to real-world data.

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 American Society of Clinical Oncology annual meeting.

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.

Remote care reduced readmissions and improved functional outcomes in COPD in a recent study.

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients treated for pediatric acute myeloid leukemia (AML).

A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug combination sensitivities, paving the way for improved treatment strategies and outcomes in acute myeloid leukemia (AML).

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β-thalassemia.

Researchers study long-term safety of lentiviral gene therapy in primates, finding no evidence of somatic mutations or malignancy.

A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.

Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.

A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that although several instruments demonstrate strong psychometric properties and reliability, significant gaps remain in these tools' validation and methodological rigor.

Real-world study compares the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), finding that axi-cel provides superior progression-free survival but with higher toxicity.

Gene therapy partially restores visual processing in the geniculostriate pathway of patients with Leber congenital amaurosis type 2 while maintaining compensatory activity in the retinotectal pathway.

Researchers review the safety, efficacy, and considerations for COVID-19 vaccination in multiple sclerosis patients, especially those on disease-modifying therapies, affirming the vaccine's overall benefit in reducing severe COVID-19 risks without significantly increasing MS relapse rates.

A new study shows that COVID-19 infection significantly increases the risk of exacerbation in patients with myasthenia gravis (MG).